Akeso company profile

9926 · HKEX · HKD

Compare Akeso
$56.70Change from previous close: −7.05%Absolute change: −$4.30

Close · November 20, 2026

Company profile

Akeso has 4,082 employees and is headquartered in Zhongshan, China.

Based in Zhongshan, China, Akeso, Inc. was founded in 2012 and develops antibody drugs for cancer and immune-related diseases. Its research, development, manufacturing and commercialization activities cover markets worldwide. The pipeline centers on bispecific antibodies, including AK104, a PD-1/CTLA-4 candidate for cervical, gastric, lung and liver cancers, and AK112, a PD-1/VEGF candidate for several solid tumors. Other programs include AK117, a CD47 antibody for hematologic cancers, and AK101, AK111, AK120 and AK102, targeting psoriasis, ulcerative colitis, ankylosing spondylitis, atopic dermatitis and hypercholesterolemia. Penpulimab and tagitanlimab are directed at nasopharyngeal carcinoma.

In the fiscal year ended December 2025, the company reported revenue of CNY 3.1 billion, up 43.9% from the previous year, and a net loss of CNY 1.1 billion. It had 4,082 employees, and its headquarters are in Zhongshan.

Company facts

Industry
Biotechnology
Headquarters
No. 6, Shennong Road, 528437, Zhongshan
Employees
4,082
Chief executive
Yu Xia
Founded
2012
Fiscal year
January - December
Listing
9926 · HKEX
Currency
HKD
ISIN
KYG0146B1032

Akeso and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Akeso9926Hong Kong SAR China$6.81B4,082-30.7%—
Genscript Biotech1548Hong Kong SAR China$8.77B6,13514.9%—
Haisco Pharmaceutical Group002653China$8.97B5,59721.1%44.1
ALTEOGEN196170South Korea$9.05B18147.2%97.1
3SBio1530Hong Kong SAR China$4.56B6,06860.3%3.90
Pharmaron Beijing300759China$10.59B25,08814.0%39.3

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Akeso with its competitors